Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Enwei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	360.09	370.27	236.12	341.58	64.25	63.02
Trading Asset Securities	174.98	144.72	157.16	236.56	14.4	14.4
Cash & Short-Term Investments	535.07	515	393.28	578.14	78.65	77.42
Cash Growth	-3.35%	30.95%	-31.97%	635.07%	1.59%	25.24%
Accounts Receivable	281.43	296.53	265	245.28	192.91	220.59
Other Receivables	4.49	3.69	3.99	4.17	3.98	3.43
Receivables	285.92	300.22	268.98	249.45	196.89	224.02
Inventory	112.89	115.55	107.37	104.65	110.01	78.34
Other Current Assets	22.49	21.27	17.23	25.06	28.21	29.01
Total Current Assets	956.38	952.04	786.86	957.29	413.77	408.79
Property, Plant & Equipment	265.63	246.55	231.12	240	241.77	224.15
Long-Term Investments	-	0.37	0.37	0.35	0.42	0.85
Goodwill	100.55	100.55	100.55	100.55	100.55	100.55
Other Intangible Assets	125.33	133.37	148.04	42.08	47.45	52.26
Long-Term Deferred Tax Assets	5.35	4.64	3.05	1.8	1.74	1.83
Long-Term Deferred Charges	7.89	8.7	10.68	16.83	18.28	19.76
Other Long-Term Assets	54.85	58.3	56.81	47.18	45.11	40.68
Total Assets	1,516	1,505	1,337	1,406	869.09	848.86
Accounts Payable	56.72	49.49	30.94	36.88	33.64	45.95
Accrued Expenses	50.49	132.83	141.69	141.02	128.52	147.3
Current Portion of Long-Term Debt	-	10.09	-	-	-	-
Current Portion of Leases	-	1.27	0.88	-	-	-
Current Income Taxes Payable	-	6.52	10.21	11.23	8.19	12.69
Current Unearned Revenue	16.94	24.61	14.01	28.15	16.15	13.89
Other Current Liabilities	108.42	13.6	12.04	10.31	12.73	14.35
Total Current Liabilities	232.56	238.42	209.77	227.58	199.22	234.18
Long-Term Debt	180	185	-	-	-	-
Long-Term Leases	0.87	1.52	0.46	-	-	-
Long-Term Unearned Revenue	8.8	9.96	11.92	14.05	15.88	18.06
Long-Term Deferred Tax Liabilities	10.88	11.96	12.17	11.45	11.74	10.1
Total Liabilities	433.11	446.86	234.31	253.08	226.84	262.34
Common Stock	102.89	102.89	70.14	70.14	52.6	52.6
Additional Paid-In Capital	643.77	638.71	671.51	664.63	239.22	239.22
Retained Earnings	395.4	375.25	392.32	418.23	350.43	294.7
Treasury Stock	-59.18	-59.18	-30.78	-	-	-
Total Common Equity	1,083	1,058	1,103	1,153	642.25	586.52
Shareholders' Equity	1,083	1,058	1,103	1,153	642.25	586.52
Total Liabilities & Equity	1,516	1,505	1,337	1,406	869.09	848.86
Total Debt	180.87	197.88	1.34	-	-	-
Net Cash (Debt)	354.21	317.12	391.94	578.14	78.65	77.42
Net Cash Growth	6.59%	-19.09%	-32.21%	635.07%	1.59%	49.41%
Net Cash Per Share	3.54	3.14	3.81	6.85	1.01	1.06
Filing Date Shares Outstanding	99.72	101.08	100.99	103.8	77.85	77.85
Total Common Shares Outstanding	99.72	99.73	102.76	103.8	77.85	77.85
Working Capital	723.82	713.62	577.09	729.7	214.55	174.61
Book Value Per Share	10.86	10.61	10.74	11.11	8.25	7.53
Tangible Book Value	857	823.74	854.59	1,010	494.25	433.71
Tangible Book Value Per Share	8.59	8.26	8.32	9.73	6.35	5.57
Buildings	-	289.03	287.63	275.1	274.06	239.09
Machinery	-	301.77	302.77	271.99	263.51	237.07
Construction In Progress	-	40.37	8.82	35.68	23.84	46.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.